Key Takeaways for Hims & Hers Health Stock as of August 2026
- Year-Long Slide: Hims & Hers Health (HIMS) stock has fallen 40.3% over the past year, closing at $28.15 on August 14 after a Q2 report that swung the company to an $86.3M net loss.
- Margin Compression: Gross margin dropped to 64% in Q2, down 12 points YoY, even as revenue rose 38% YoY to $753.2M and subscribers grew 19% to ~2.89M.
- Street Split: Analysts currently carry 1 buy, 2 outperforms, 11 holds, 1 no opinion, and 1 underperform on HIMS stock, with a mean target of $29 sitting about 5% above the current price.
- Model Verdict: TIKR’s mid-case model targets $29 for HIMS stock by December 2030, implying just 5% total return and 1% annualized over the next 4.4 years.
Why Hims & Hers Stock Has Fallen 40% Despite Record Subscriber Growth
Hims & Hers Health (HIMS) stock has dropped 40.3% over the past year, a slide that has continued even as the company keeps beating revenue estimates. The second-quarter report released August 10 showed revenue up 38% year over year to $753.2 million, ahead of the $699.89 million analysts expected, alongside 300,000 net new subscribers and a subscriber base approaching 2.9 million. None of it stopped the stock from falling.
The reason sits in the gross margin line. It fell to 64% in the quarter, down 12 points from 76% a year earlier, as the mix shifted toward lower-margin branded weight-loss drugs and international revenue following the Eucalyptus acquisition. CFO Yemi Okupe was direct about the trade-off on the earnings call: “As branded weight loss products and international revenue become a larger portion of the business, we expect gross margins will remain below the levels we have historically achieved.” That single sentence is why a 38% revenue beat still produced an $86.3 million net loss, versus a profit a year earlier, and a per-share loss of $0.37 against a Street estimate of a one-cent loss.
Two more events compounded the pressure. On July 29, the FTC sued Hims & Hers, alleging the company shared users’ health data with Meta and Snap despite promising privacy, and used deceptive billing and cancellation practices; the stock dropped roughly 14% the day the news broke. Then, on August 12, Wall Street turned cautious on the company’s coming peptides launch, with analysts noting that legally available offerings like NAD+ face grey-market competition that limits their revenue impact this year.
Hims & Hers stock is now caught between real growth and a business model that costs more to run than it used to, and neither the FTC case nor the peptides timeline gives the market a clean reason to look past the margin story yet.
Analysts Have Cut Targets in Half Since Mid-2025, Then Stalled
The current Street view on HIMS stock is narrowly bullish at best: 1 buy, 2 outperforms, 11 holds, 1 no opinion, and 1 underperform among 13 analysts publishing price targets. The mean target sits at $29, about 5% above the $28.15 close, while the median target of $27 sits below it. That’s a Street that has largely converged on “hold” rather than taking a strong view in either direction.
The trend explains the caution. Back on June 30, 2025, the mean target stood at $49.80, matching a price close of $49.85. Both collapsed together through the back half of last year and into March 2026, when the target bottomed at $24.15 against a $20.76 close. Targets and price both recovered by June 30, 2026, with the mean target reaching $26.88 and the price hitting $34.67.
Since then the price has fallen back to $28.15 while the mean target actually rose to $29.46, a divergence that shows analysts holding their ground even as the stock gave back its summer gains. Buy ratings have shrunk from 4 a year ago to 1 today, and sell ratings have disappeared entirely, evidence that the Street has settled into a wait-and-see posture rather than a bearish one.
TIKR Values Hims & Hers Stock at $29, Pricing In Limited Near-Term Upside
TIKR’s mid-case model values Hims & Hers stock at $29 by December 2030, implying a 4.5% total return from the current price of $28.15, or roughly 1% annualized over the next 4.4 years.
That return trails what growth-stage health care names typically need to clear to justify holding through a margin transition, and it lands close to the Street’s own $29 mean target rather than above or below it.
The model’s modest number reflects the same tension driving the stock lower now. Revenue and subscriber growth remain strong, but the margin compression Okupe described on the call has no clear end date, and neither the FTC litigation nor the peptides rollout offers a near-term margin offset. Until gross margin stabilizes, the model sees Hims & Hers stock as priced close to fair value rather than discounted.
That reading also matches the multiple. HIMS stock trades at 18.86 times forward earnings, well below its 35.21 times mean over the past year and down sharply from a 77.73 times peak in July, when compressed near-term earnings estimates inflated the ratio. The multiple has already reset lower alongside the margin story, leaving little room for a re-rating until profitability recovers.
Should You Invest in Hims & Hers Health, Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Hims & Hers Health, Inc. stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Hims & Hers Health, Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze HIMS stock on TIKR for Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
